- Global Pharma News & Resources

Orgenesis Achieves Revenue of USD 7.2 Million for the Second Quarter of 2022

Orgenesis Achieves Revenue of USD 7.2 Million for the Second Quarter of 2022

  • Secures Funding from Metalmark Capital Partners to Drive Growth
  • Orgenesis to Host Conference Call Today, August 16, 2022 at 11 AM Eastern Time

Germantown, Maryland, US, August 17, 2022 - Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for second quarter ending June 30, 2022.


Vered Caplan, CEO of Orgenesis, said, “We are progressing with our transition to the second phase of the planned rollout of our POCare platform. This includes revenue generation from the validation, process development, and supply of advanced therapies that utilize our POCare platform and Orgenesis Mobile Processing Units and Labs (OMPULs). As a result of the successful execution of the first phase, our global supply network now spans North America, Europe, Asia, and the Middle East. Within the U.S. specifically, we are expanding our capacity and collaborations with a number of leading global healthcare institutions such as Johns Hopkins to establish a new POCare Center, also known as the Maryland Center for Cell Therapy Manufacturing.”


“Feedback from within the industry based on Orgenesis’ progress has been overwhelmingly positive. This is a result of our ability to reduce costs and add capacity in significantly less time than required for traditional clean rooms. We have multiple contracts with biotech companies from the U.S., E.U., Asia and the Middle East. Importantly, we believe we have built a highly scalable business model, and expect to benefit from growth in high margin, recurring revenue streams, based on future royalties and long-term contracts for industrializing and supplying these cell and gene therapies.”

Ms. Caplan continued, “I am pleased to report that we secured a USD 10 million loan within our newly formed subsidiary for Orgenesis’ point of care services business for treating patients (POCare Services) with Metalmark Capital Partners, a premier investment firm with deep expertise in the healthcare sector. Metalmark will provide ongoing advice to help us accelerate the rollout of our POCare platform and these critical CGT services.”


“In addition to our POCare Services platform, we are advancing our POCare therapeutic pipeline, which now spans over 16 distinct clinical programs in the field of immuno-oncology, anti-viral, metabolic/auto-immune diseases, and tissue regeneration. Our cost-efficient strategy involves leveraging government grants and funding from regional partners for our innovations and in-licensed therapies from leading research centers, hospitals and biotech companies. Most recently, in May 2022, we were awarded a EUR 4M European Innovation Council Pathfinder Grant to advance technologies for the production of personalized autologous induced pluripotent stem cells (iPSCs) that can be utilized for regenerative medicine. Overall, we believe our therapeutic pipeline holds unlocked potential as we advance each of these assets through key clinical and pre-clinical milestones.”


The complete financial results for the second quarter of 2022 and details on the USD 10 million loan to our subsidiary are available on the Company’s website in the Company’s Form 10-Q and 8-K, respectively, which have been filed with the Securities and Exchange Commission.


Conference Call

The Company will host a conference call today, August 16, 2022, at 11:00 AM Eastern Time to discuss the company’s corporate progress and other developments.


The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code 223911. A webcast of the call may be accessed at or on the Company’s Investor Events section of the website here.


A webcast replay will be available on the Company’s Investor Events section of the website ( through Wednesday, August 16, 2023. A telephone replay of the call will be available approximately one hour following the call, through Tuesday, August 30, 2022 and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 46399.

Editor Details

Last Updated: 18-Aug-2022